Welcome to our dedicated page for Clene news (Ticker: $CLNN), a resource for investors and traders seeking the latest updates and insights on Clene stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clene's position in the market.
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) provided an ALS regulatory update from its recent meeting with the U.S. Food and Drug Administration (FDA) regarding CNM-Au8® for the treatment of ALS. The FDA determined that the initial findings on biomarker NfL reduction from the Phase 2 programs were insufficient to support accelerated approval at this time. Clene plans to provide supplemental data for further engagement with the FDA, including additional long-term clinical evidence and biomarker results in the first half of 2024. The company also supports ongoing CNM-Au8 compassionate use programs and plans to launch a Phase 3 ALS confirmatory study in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.46%
Tags
-
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) and its subsidiary Clene Nanomedicine Inc. announce the successful Phase 2 REPAIR clinical studies for CNM-Au8® in treating neurodegenerative diseases. The studies show significant increase in brain NAD+/NADH ratio, ATP levels, and phosphorylation potential, indicating favorable modulation of brain energy metabolites. The results are published in the Journal of Nanobiotechnology, signaling a significant advancement in the treatment of Parkinson’s disease and multiple sclerosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
-
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8® in the RESCUE ALS open-label extension trial. The company also announced a statistically significant long-term survival benefit of 70% decreased risk of death associated with CNM-Au8 treatment in the HEALEY ALS Platform Trial. Additionally, they were awarded a $45.1 million NINDS grant to support research and expanded access of CNM-Au8 in people living with ALS and announced a peer-reviewed publication characterizing CNM-Au8 neuroprotective mechanism of action in a nanotechnology-focused journal. Clene's cash and cash equivalents totaled $42.1 million as of September 30, 2023, and they expect their resources to be sufficient to fund operations into the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
Rhea-AI Summary
Clene Inc. receives a $45.1 million grant from NINDS to support an Expanded Access Protocol for its investigational drug, CNM-Au8, in ALS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.2%
Tags
-
Rhea-AI Summary
Clene Inc. announces the publication of a scientific paper describing the catalytic mechanism of action of its drug CNM-Au8 in neurodegenerative diseases. CNM-Au8 treatment promotes cell survival and preservation of neurite networks. The drug is being investigated as a potential first-in-class treatment for ALS, MS, and PD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
-
Rhea-AI Summary
Clene Inc. (CLNN) to participate in Cantor Fitzgerald Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.22%
Tags
Rhea-AI Summary
Clene Inc. announces long-term follow-up data for patients treated with CNM-Au8 30mg in the HEALEY ALS Platform Trial, showing improved survival with a 49% decreased risk of death compared to PRO-ACT placebo (p=0.046). Pooled analysis with RESCUE-ALS Trial shows a 59% decreased risk of death (p=0.004). No safety signals observed with over 500 patient years of CNM-Au8 treatment exposure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) to participate in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.04%
Tags
-
Rhea-AI Summary
Clene Inc. announces significant survival benefit and decreased risk of ALS worsening events with CNM-Au8 treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
Rhea-AI Summary
Clene Inc. (CLNN) announced significant reductions in plasma neurofilament light chain levels compared to placebo in patients treated with CNM-Au8 in the HEALEY ALS Platform trial. The company also reported results of the Phase 2 RESCUE ALS study and its open-label extension, as well as a grant from the National Multiple Sclerosis Society to fund Cohort 2 of REPAIR-MS, a Phase 2 clinical study. Clene expects multiple near-term data announcements to support the benefit and safety of CNM-Au8 in ALS patients. The company's cash, cash equivalents, and marketable securities total $49.2 million as of June 30, 2023, including gross proceeds of $40 million from a recent public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
Clene Inc.
Nasdaq:CLNN
CLNN Rankings
CLNN Stock Data
47.78M
67.91M
40.13%
19.28%
0.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SALT LAKE CITY
About CLNN
clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.